Daiichi Sankyo Company, Limited

Kathrin-Ladetzki Baehs

Tohru Takahashi

Eisuke Tsuda

Yoshiharu Hiruma

Toshinori Agatsuma

Toshiaki Ohtsuka

Tatsuji Matsuoka

Ichiro Watanabe

Ingrid Schuster

Dirk Ponsel

Sandra Miller

Ulrike Schubert

Robert Mühlbacher

Steffen Runz

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Antibody targeting osteoclast-related protein Siglec-15

Growing community of inventors

Munich, Georgia

Kathrin-Ladetzki Baehs